€157K Funding Boost for Amporin Pharmaceuticals’ Degenerative Disease Treatment

Swiss company Amporin Pharmaceuticals has secured a €157,000 (CHF 150,000) investment from Venture Kick to advance the development of amyloid pore inhibitors aimed at treating deadly degenerative diseases. Amporin’s mission is to create and license the first effective acute oral disease-modifying treatments for up to six major diseases, initially targeting Parkinson’s disease and ALS (amyotrophic lateral sclerosis).

Over 50 deadly degenerative diseases, such as Alzheimer’s, Parkinson’s, type II diabetes, and numerous rare neurodegenerative disorders, are linked to protein misfolding and aggregation. Despite the critical need, no treatments currently exist that can halt or reverse the progressive degeneration these conditions cause, ultimately leading to death. Amporin Pharmaceuticals is developing a new class of small-molecule drugs designed to block and eliminate toxic soluble oligomers and pores within cell membranes. These toxic substances accumulate and cause cell death by creating holes in cell membranes, disrupting cellular homeostasis and leading to progressive degeneration.

The founding team of Amporin Pharmaceuticals comprises CEO Dr. Kelvin Stott, CSO Dr. Hervé Schaffhauser, and CMO Prof. Daniel Umbricht. Each member brings over 20 years of experience in CNS drug development and R&D leadership from both Big Pharma companies and biotech startups. Venture Kick has been a critical source of support in helping us to build a world-class company around a world-changing technology,” emphasized Kelvin Stott, Co-Founder and CEO of Amporin Pharmaceuticals.

The recent funding will enable Amporin to establish its core operations and develop a comprehensive in vitro data package. This package aims to validate and showcase the unique advantages of Amporin’s technology to potential investors and licensing partners.

Amporin Pharmaceuticals is poised to revolutionize the treatment of degenerative diseases by addressing a critical unmet need in medical science. With the potential to improve and extend the lives of millions affected by these devastating conditions, Amporin is set to make a significant impact. The company is developing a new class of small-molecule drugs that specifically target and eliminate toxic oligomers and pores within cell membranes. These toxic substances, resulting from protein misfolding and aggregation, accumulate in cells, causing them to degenerate and die by puncturing holes in the membranes. This process leads to the loss of cellular homeostasis and progressive degeneration characteristic of over 50 deadly degenerative diseases, including Alzheimer's, Parkinson’s, type II diabetes, and many rare neurodegenerative disorders.

Currently, no effective treatments exist to halt or reverse the progression of these diseases. Amporin’s approach focuses on creating the first effective acute oral disease-modifying treatments, which could transform the therapeutic landscape for conditions like Parkinson’s, ALS, Alzheimer's, and type II diabetes. Initially, the company is concentrating its efforts on Parkinson’s disease and ALS (amyotrophic lateral sclerosis), with plans to extend its research and development to other major diseases.

Amporin Pharmaceuticals has secured a €157,000 (CHF 150,000) investment from Venture Kick to advance its pioneering work. This funding will enable the company to establish its core operations and develop a comprehensive in vitro data package to validate and demonstrate the unique advantages of its technology to potential investors and licensing partners. The founding team of Amporin includes CEO Dr. Kelvin Stott, CSO Dr. Hervé Schaffhauser, and CMO Prof. Daniel Umbricht, each bringing over 20 years of experience in CNS drug development and R&D leadership from multiple Big Pharma companies and biotech startups. Their expertise and vision are critical in driving the company’s mission forward.

“Venture Kick has been a critical source of support in helping us to build a world-class company around a world-changing technology,” highlighted Kelvin Stott, Amporin Pharmaceuticals’ Co-Founder and CEO. In summary, Amporin Pharmaceuticals is at the forefront of developing groundbreaking treatments for degenerative diseases. Their innovative small-molecule drugs have the potential to fill a significant gap in medical science by offering the first effective treatments that modify the course of these diseases, ultimately improving and extending the lives of millions worldwide.